cisapride has been researched along with nifedipine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Jia, L; Sun, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Lepsien, G; Lüdtke, FE; Neufang, T; Schramek, P | 1 |
| Grönniger, J; Hillemanns, A; Oglodek, C; Reinbold, WD | 1 |
| Sammarco, J; Washabau, RJ | 1 |
| Aizawa, O; Hongo, K; Kashiwagi, H; Mochizuki, S; Okamura, T; Sakai, T; Satoh, C; Watanabe, H | 1 |
| Abe, J; Hamada, Y; Harada, T; Hashimoto, K; Horii, I; Sawada, Y; Shiotani, M | 1 |
| de Boer, TP; Duker, G; Jonsson, MK; Mirams, GR; Sartipy, P; van Veen, TA; Vos, MA | 1 |
| Amuzescu, B; Eisfeld, J; Frech, S; Knott, T; Lin, KH; Scheel, O | 1 |
21 other study(ies) available for cisapride and nifedipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Cisapride effects on canine lower esophageal sphincter under various pharmacological pretreatments.
Topics: Animals; Atropine; Calcium Channels; Cisapride; Dogs; Esophagogastric Junction; Muscle Relaxation; Nifedipine; Piperidines; Pressure; Receptors, Muscarinic; Serotonin Antagonists | 1991 |
[Leiomyomatosis of the esophagus].
Topics: Anti-Ulcer Agents; Biopsy; Cisapride; Combined Modality Therapy; Deglutition Disorders; Esophageal Neoplasms; Esophagus; Follow-Up Studies; Humans; Leiomyomatosis; Magnetic Resonance Imaging; Male; Middle Aged; Nifedipine; Omeprazole; Pathology; Piperidines; Tomography, X-Ray Computed | 1994 |
Effects of cisapride on feline colonic smooth muscle function.
Topics: Acetylcholine; Animals; Atropine; Calcium; Calcium Channels; Cats; Cholecystokinin; Cholinergic Agonists; Cisapride; Colon; Electric Stimulation; In Vitro Techniques; Isometric Contraction; Muscle, Smooth; Neurotensin; Nifedipine; Piperidines; Substance P; Tetrodotoxin | 1996 |
Influence of cisapride on the pharmacokinetics and antihypertensive effect of sustained-release nifedipine.
Topics: Aged; Calcium Channel Blockers; Cisapride; Delayed-Action Preparations; Drug Interactions; Female; Gastric Emptying; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Hypertension; Male; Middle Aged; Nifedipine; Piperidines | 1996 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; Electrocardiography; Guinea Pigs; Haloperidol; Heart; Humans; Injections, Intravenous; Long QT Syndrome; Male; Nifedipine; Pimozide; Piperidines; Pyridines; Quinidine; Reproducibility of Results; Telemetry; Terfenadine; Thioridazine | 2005 |
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Action Potentials; Arrhythmias, Cardiac; Benzazepines; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Signaling; Cells, Cultured; Cisapride; Drug Evaluation, Preclinical; Embryonic Stem Cells; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Myocytes, Cardiac; Nifedipine; Patch-Clamp Techniques; Sodium Channels | 2012 |
Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology.
Topics: Action Potentials; Anesthetics, Local; Automation; Calcium Channel Blockers; Cells, Cultured; Cisapride; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Nifedipine; Patch-Clamp Techniques; Reproducibility of Results; Serotonin Receptor Agonists; Tetrodotoxin | 2014 |